Dicot is devoted to Research and Develop- ment of novel drugs with with a large market potential.
We perform high-end chemical and biological research isolating natural products and characteri- zing their biological effects. The active components are structurally determined and effective methods for their chemical synthesis is developed. This is followed by safety evaluations for clinical trials and registration as marketable pharmaceuticals.
Libiguins - remarkably potent and long effect duration compounds for erectile dysfunction and premature ejaculation
A key product in pipeline is a new principle termed libiguin for treatment of erectile dysfunction and premature ejaculation with a remarkably high potency and long effect duration, which is developed as a registered drug based on a synthetic libiguin derivative. Libiguins show properties for the treatment of erectile dysfunction and premature ejaculation which are unmet by current medications on the market.
All Research and Development is complemented with an effective patenting policy to protect the immaterial rights to our discoveries.
Our research is performed by in-house and external networks of highly qualified researchers in Chemistry, Biology and Pharmacology, and key-personnel in natural resources. Our deployment is spread across University and Private resources.
News time line
Dicot enroles experienced project leader
January 9, 2017
Dicot accepted on Nordic Pre Market
December 19, 2016
European patent office approves Dicot patent for libiguins
April 12, 2016
Australian patent office approves Dicot patent for libiguins
January 22, 2015